Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 629

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 629
---
 to New Semnur’s business of environmental, social and governance issues, and its public reporting on these topics; |

| • |     | considering any recommendations for nominees and proposals submitted by stockholders; and |

| • |     | monitoring and recommending modifications to New Semnur’s insider trading policy, if necessary or advisable, to the New Semnur Board. |

The nominating and corporate governance committee will periodically review, discuss and assess the performance of the New Semnur Board and the committees of the New Semnur Board. In fulfilling this responsibility, the nominating and corporate governance committee will seek input from senior management, the New Semnur Board and others. In assessing the New Semnur Board, the nominating and corporate governance committee will evaluate the overall composition of the New Semnur Board, the New Semnur Board’s contribution as a whole and its effectiveness in serving New Semnur’s best interests and the best interests of New Semnur’s stockholders. The nominating and corporate governance committee will review, discuss and assess its own performance and composition at least annually. The nominating and corporate governance committee will also periodically review and assess the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommend any proposed changes to the New Semnur Board for its consideration and approval. The composition and functioning of the nominating and corporate governance committee will comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. New Semnur intends to comply with future requirements to the extent they become applicable to New Semnur. 384

Code of Business Conduct and Ethics New Semnur intends to adopt a written code of business conduct and ethics, effective immediately prior to the closing of the Business Combination, which will apply to New Semnur’s directors, officers and employees, including New Semnur’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon the closing of the Business Combination, a current copy of New Semnur’s code of business conduct and ethics will be posted on its website at www.semnurpharma.com. Information contained on or accessible through such website is not a part of this proxy statement/prospectus, and the inclusion of the website address in this proxy statement/prospectus is an inactive textual reference only. New Semnur intends to disclose any amendments to its code of business conduct and ethics, or any waivers of